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Abstract
Scientiﬁc interest in the aetiological relationship between infectious diseases and cancer is constantly increasing for numerous reasons.
First, increased numbers of neoplasias have been deﬁnitely aetiologically correlated with speciﬁc pathogens. Second, the pathways that
lead to carcinogenesis have shed light on numerous important cellular processes. Third, infection as a cause of cancer is preventable,
and thus cancer is preventable, either at a primary stage by inhibition of infection or, secondarily, by inhibition of the carcinogenic pro-
cess. The latter reason lies behind two of the major public health campaigns of recent years, namely vaccination for hepatitis B virus
and human papilloma virus.
Cancer remains a modern plague, both in terms of
morbidity/mortality and economic costs, but also regarding
the understanding of its evolution and development of ther-
apeutic interventions. The burden of cancer is particularly
troublesome given that it essentially represents a constella-
tion of diseases, each with a distinct pathogenesis and prog-
nosis. Cancers that are a direct consequence of infectious
processes are, in this frame, signiﬁcant for two reasons. First,
understanding the process by which an infection leads to the
development of cancer sheds light on major cellular path-
ways that are involved in carcinogenesis; in this context,
viruses in particular have been characterized as the ‘Rosetta
stone for unlocking the mysteries of cell growth control’ [1].
Dissimilar to the effect of environmental factors, for exam-
ple, infection is a deﬁnite event, often of measurable burden,
that can be traced and studied over time in many instances.
Second, infection as a cause of cancer is preventable, either
in a primary mode through vaccination or, secondarily, by
inhibiting, through therapy, the chronic disease that is a pre-
requisite for carcinogenesis in certain situations.
Our understanding of the relationship between infectious
agents and cancer can be illustrated as a timeline (Fig. 1).
The interest of the scientiﬁc community in this potential cor-
relation (and the will and the need to believe in it) is
depicted by the fact that the Nobel Prize for Medicine has
often been awarded to scientists who apparently proved
such a relationship (even if their ﬁndings were subsequently
shown to be wrong) [2]. The timeline shows the richness of
discoveries and awards (upper half of Fig. 1), and the dearth
of therapeutic interventions (lower half of Fig. 1). It also
shows a signiﬁcant clustering of the important events, with a
signiﬁcant gap during the early post-World War II period,
when scientiﬁc interest was mainly focused on combating
infectious diseases through antibiotics, and the pathogens’
collateral effects, including carcinogenesis, gathered little
attention [2]. It has to be said, however, that this period was
noteworthy for its recognition of viruses with animal onco-
genic potential.
The list of infectious agents associated with carcinogene-
sis, either deﬁnitely or speculatively, is continually growing,
and new neoplasias are correlated with acknowledged onco-
genic pathogens. The typical example is Epstein–Barr virus
(EBV) which, beyond Burkitt’s lymphoma, as demonstrated in
this issue in the review by Shah and Young, is aetiologically
implicated. Even more illustrative, perhaps, is the develop-
ment of nasopharyngeal cancer.
Less than 30 years ago, the notion of correlating gastric
cancer with a bacterial pathogen would have appeared futile;
there were numerous attempts to demonstrate this correla-
tion, but scientiﬁc shortcomings may have delayed the recog-
nition of the infectious origin of peptic ulcer disease and,
subsequently, gastric cancer. There is nothing more charac-
teristic than the story of John Lykoudis, a Greek general
practitioner working in a rural setting; during the late and
the 1960s, he treated more than 50 000 gastritis patients,
including himself, with a combination of antibiotics. His pio-
neering ideas were met with hostility, however, by both the
national medical authorities (he was actually ﬁned for treat-
ing patients in this manner) and the international scientiﬁc
community (his study famously having been rejected by the
Journal of the American Medical Association) [3]. Today, the
correlation between Helicobacter pylori and gastric cancer is
more than deﬁnite, as discussed in the review by Herrera
and Parsonnet in this issue.
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A deﬁnite correlation between a number of infectious
agents and human cancer has been demonstrated, and there
are potential carcinogenic agents for which, at least at pres-
ent, the correlation has not been satisfactorily substantiated
(Table 1). Some of the possibly implicated agents, such as
the polyoma viruses, possess typical oncogenic properties,
and the absence of a deﬁnite correlation with cancer may be
attributed to difﬁculties in recognizing their presence or
their aetiological effect. On the other hand, oncogenic prop-
erties have been recognized in adenoviruses, but any correla-
tion with a speciﬁc cancer is absent in their case [4]. The list
includes predominantly viruses, although bacteria and para-
sites are also implicated.
The burden of annual morbidity related to potentially pre-
ventable neoplasia is huge, and its signiﬁcance is aggravated
by the fact that certain of these malignancies are clustered in
speciﬁc world areas, as, for example, hepatitis B virus-related
hepatocellular carcinoma in Southeast Asia which is discussed
in the review by Fung et al. in this issue. Infectious agents are
responsible for almost 22% of deaths as a result of cancer in
the developing world and 6% in industrialized countries. For
2002, 1.9 million cancers were directly attributed to infec-
tious agents worldwide, which is equal to 17.8% of the global
cancer burden, with the percentage reaching 26% in the
developing world and being as low as 8% in developed coun-
tries [5]. This burden appears to be especially disproportion-
ate when considering certain patient subpopulations; for
example, HIV-positive individuals in whom human herpes
virus-8 exerts the majority of its oncogenic potential
(Table 1).
Cancer can be induced by an infectious agent through
multiple pathways [2]. A pathogen can directly induce carci-
nogenesis by interfering with the expression of oncogenes or
tumour-suppressing genes; this is the case with human papil-
loma virus, EBV, human herpes virus-8, and human T-cell
lymphotropic virus-1. Chronicity of an infection with subse-
quent inﬂammation may lead to the production of cell- and
DNA-harmful substances and the alteration of the normal
cell cycle; this is the pathogenetic mechanism implicated in
carcinogenesis related to hepatitis viruses, H. pylori, and the
parasites. Finally, infectious agents can induce immune sup-
pression that serves as a matrix upon which carcinogenesis
evolves; the pathogenesis in this case may overlap with
the chronic inﬂammation pathway, but is also the typical
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FIG. 1. A timeline of aetiological correlation
of cancer with infectious diseases. EBV, Epstei-
n–Barr virus; HBV, hepatitis B virus; HHV8,
human herpes virus-8; HPV, human papilloma
virus.
TABLE 1. Infectious causes of cancer and the annual burden
Pathogen Implicated in
Annual cases
attributed toa
Deﬁnite causes of cancer
Epstein–Barr virus Burkitt’s lymphomab 100 000
Nasopharyngeal cancer
Also implicated in: gastric carcinoma
Helicobacter pylori Gastric cancerb 490 000
Gastric mucosal associated
lymphoid tissue lymphoma
Hepatitis B virus Hepatocellular carcinoma 280 000
Hepatitis C virus Hepatocellular carcinoma 110 000
Human herpes virus-8 Sarcoma Kaposi 55 000
Primary effusion lymphoma
Multicentric Castleman’s disease
Human papilloma virus Cervical cancer 550 000
Anal cancer
Also implicated in: vulvar,
vaginal, penile cancer
Human T-cell
Lymphotropic virus
Acute T-cell leukaemia 2700
Opisthorchis viverrini Cholangiocarcinoma 800
Schistosoma haematobium Bladder cancer 9000
Possible/indirect causes of cancer
Clonorchis sinensis
/Opisthorchis felineus
Cholangiocarcinoma
HIV Increased potential lymphomas
(including central nervous system);
synergy-like action with naHHV8
Polyoma viruses
JCV Brain tumours
BKV Brain tumours
SV40 Osteosarcoma, mesothelioma
Schistosoma japonicum Colorectal cancer,
hepatocellular carcinoma
aData derived from WHO [6].
bCofactors needed; can be considered as necessary but not adequate factor.
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background created by HIV, upon which certain neoplasias
may develop.
By deﬁnitely attributing a particular neoplasia to a spe-
ciﬁc infectious agent, the path to prevention through elimi-
nation of the initiating event (infection or its carcinogenic
actions post-infection) has understandably drawn scientiﬁc
attention, and already accounts for some of the most
promising public health campaigns that may lead to deterio-
ration of the incidence and mortality of numerous malignan-
cies. The most recent and characteristic example is human
papilloma virus, the relationship of which with cervical can-
cer (and the issues ensuing from the recent initiation of
mass vaccination) is covered in detail in the comprehensive
review by Galani and Christodoulou in this issue. Mass
vaccination for hepatitis B virus has already resulted in
major decreases in the incidence of hepatocellular carci-
noma in endemic areas [7]. Development of a hepatitis C
vaccine and EBV remains a difﬁcult task [8, 9], but regres-
sion of chronicity through antiviral treatment has been suc-
cessful for the former.
As depicted in the timeline (Fig. 1), the correlation
between infectious agents and cancer is increasingly recog-
nized and further research should focus on the identiﬁca-
tion of hitherto unknown pathogens that are aetiologically
implicated in cancer. Other stories similar to that of John
Lykoudis may remain to be told.
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